This commentary focuses on the cytopathology laboratory, the authors' experiences with coronavirus (COVID‐19) in Taiwan, and current guidelines on COVID‐19 infection prevention and control. The objective of this report is to provide cytopathology professionals a timely, in‐depth, evidence‐based review of biosafety practices for those at risk for coronavirus (COVID‐19) infection.